Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Creo Medical ( (GB:CREO) ) has shared an update.
Creo Medical Group plc has appointed Deutsche Numis as its Nominated Adviser, sole Broker, and Financial Adviser. This strategic move is expected to strengthen Creo’s financial advisory and brokerage capabilities, potentially enhancing its market position in the medical device industry focused on minimally invasive surgical endoscopy.
More about Creo Medical
Creo Medical Group plc is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices aimed at enhancing endoscopic procedures. The company focuses on improving patient outcomes through its advanced CROMA technology powered by Kamaptive, which integrates multi-modal energy sources to optimize surgical capabilities and provide precise, controlled solutions for procedures such as resection, dissection, coagulation, and ablation.
YTD Price Performance: -28.85%
Average Trading Volume: 905,788
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £58.78M
For an in-depth examination of CREO stock, go to TipRanks’ Stock Analysis page.